BTIG analyst Ryan Zimmerman raised his price target on OrthoPediatrics to $37 and kept his Buy rating, calling the stock his “2019 Top Pick in Musculoskeletal” sector. The analyst points to a “combination of durable demographic and epidemiological trends, stable procedural volumes within hospitals, and a robust economy spurring elective procedure demand” supporting the sector’s continued growth. Zimmerman is also positive on the company’s “strengthened balance sheet from a recent equity raise, a large total addressable market, limited competition, and a growing portfolio of niche products.”
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.